U.S. court voids $448 million award against AbbVie, AndroGel partner By Reuters

U.S. court voids $448 million award against AbbVie, AndroGel partner

© Reuters. A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange

(Reuters) – A federal appeals court on Wednesday reversed an order that had required AbbVie Inc (N:) and a partner to disgorge $448 million in profit, in antitrust litigation brought by the U.S. Federal Trade Commission related to the testosterone replacement drug AndroGel.

The 3rd U.S. Circuit Court of Appeals in Philadelphia said a lower court judge who ordered the disgorgement lacked authority to do so under applicable federal law. It also upheld an order finding AbbVie and its partner Besins Healthcare Inc liable for monopolization, and reinstated some FTC claims.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.